Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPN-375 (fluticasone propionate) in chronic rhinosinusitis without nasal polyps
2019-000648-86Phase 3Unknown
- Sponsor
- OptiNose
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone in chronic rhinosinusitis (CRS) and rhinosinusitis (3 arms), sponsored by OptiNose. Primary endpoint: Co-primary efficacy endpoints. Status: unknown.
02
Drugs
fluticasone
03
Conditions
chronic rhinosinusitis (CRS)rhinosinusitis
Beyond the preview
Go deeper on 2019-000648-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000648-86.